Search ARM

Q1 2019 Data Report

This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

Global Landscape


Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers


Total Q1 2019 Global Financings

Total Global Financing

$2.2 Billion


Decrease from Q1 2018

Gene & Gene-modified
Cell Therapy

$2.1 Billion


Decrease from Q1 2018

Cell Therapy

$823 Million


Decrease from Q1 2018

Tissue Engineering

$14 Million


Decrease from Q1 2018

Total Global Financings by Type, by Year


Clinical trials underway
worldwide by the end of Q1 2019

PH. 1


PH. 2


PH. 3


Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

Q1 2019

Gene Therapy
Cell Therapy
Cell Therapy
Tissue Engineering

Clinical Trials by Indication: Q1 2019

Report Infographics